Patients for whom there are no existing treatments watch with desperation as a potentially helpful new drug spends years working its way from a lab bench, through clinical trials, and finally to the FDA, where reviewers consider it for approval.
In 1996, Lei Zheng, a graduate of Peking Union Medical College, enrolled in the doctorate program at what was then known as the Cancer Therapy & Research Center in San Antonio.
